BC PharmaCare: Your Voice



Get Involved

or

Read the Ongoing Results of this Engagement

 

What is this engagement about?

The Ministry of Health has two main goals for the BC PharmaCare program:

  • To cover drugs that support the health and well-being of British Columbians; and
  • To make sure that the drugs PharmaCare covers are affordable and give the best value for money.

To meet the first goal, PharmaCare covers a drug only if it has a proven record of safety and effectiveness. To meet the second goal, PharmaCare compares each drug to the drugs it already covers that treat the same condition. For example, if more than one drug provides the same health benefit, PharmaCare may cover only the drug(s) that offers the best value.

Before PharmaCare decides if it will cover a drug, the drug goes through a full review to find out if covering it aligns with the goals above. Patients, caregivers and patient groups have the opportunity to add their voices to the drug review process.

The Ministry of Health is collecting patient input for the therapeutic review of anticoagulant drugs used to treat cancer-associated thrombosis (CAT).

The anticoagulant drugs included in the review are as follows:

Generic names: dalteparin, enoxaparin, enoxaparin biosimilars, tinzaparin, nadroparin, apixaban, rivaroxaban, dabigatran, edoxaban, and warfarin

Brand names: FRAGMIN®, LOVENOX®, LOVENOX HP®, NOROMBY™, REDESCA®, INCLUNOX®, INNOHEP®, FRAXIPARINE®, FRAXIPARINE Forte®, ELIQUIS®, XARELTO®, PRADAXA®, LIXIANA®, and warfarin

Drugs used for: the treatment of cancer-associated thrombosis (CAT)

A PDF of the survey questions has been posted along with the online survey so that patients, caregivers, and patient groups can review the questions before filling it in.


The Ministry of Health is considering the following drugs for PharmaCare coverage:

Generic name: upadacitinib

Brand name: Rinvoq™

Drug used for: the treatment of psoriatic arthritis in adults.

Generic name: elexacaftor/tezacaftor/ivacaftor and ivacaftor

Brand name: Trikafta®

Drug used for: the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis   transmembrane conductance regulator (CFTR) gene.

Generic name: budesonide/ glycopyrronium /formoterol fumarate

Brand name: Breztri Aerosphere™

Drug used for: chronic obstructive pulmonary disease (COPD)

Input accepted: From Wednesday, May 19, 2021 to Wednesday, June 16, 2021 AT MIDNIGHT

To provide input, please visit the website:  http://www.health.gov.bc.ca/pharmacare/yourvoice/.

 

How can my contribution make a difference?

All responses that are submitted during the open consultation are sent to the Drug Benefit Council. The Council takes the public’s input into consideration when they make their drug coverage recommendations. Drugs are posted for review on an ongoing basis.

 

Details of the Engagement:

Date: June 6, 2017

Status: Ongoing

Location: Province-wide

Category: Health & Safety

Types: Online

 

Get Involved

or

Read the Ongoing Results of this Engagement